Poolbeg Pharma (POLB) H1 2025 earnings summary

Executive summary

• Cash balance of £10.0 million as of 30 June 2025, bolstered by a £4.865 million oversubscribed fundraise, extending cash runway into 2027.

• POLB 001 granted FDA Orphan Drug Designation for preventing Cytokine Release Syndrome (CRS) in cancer immunotherapy, enhancing commercial prospects.

• Preparations advanced for POLB 001 Phase 2a trial, with interim data expected summer 2026; supply of bispecific antibody drug secured at no cost.

• Oral GLP-1 proof-of-concept trial for obesity to commence at University of Ulster, topline data expected H1 2026.

• Pipeline targets high-value markets in oncology and obesity, with strong partnering potential on positive trial data.

Financial highlights

• Loss for the period was £2.2 million (H1 2024: £2.3 million), with R&D expenses at £0.5 million and administrative expenses at £2.0 million.

• Cash and cash equivalents stood at £9.96 million (30 June 2024: £10.06 million).

• Net proceeds from equity issue totaled £4.49 million, supporting operational runway.

• Basic and diluted loss per share was (0.43)p (H1 2024: (0.45)p).

Outlook and guidance

• Anticipates value-creating milestones from POLB 001 and oral GLP-1 trials in 2026.

• Focused on securing partnerships based on positive clinical data.

• Robust cash position supports delivery of key milestones through 2027.